These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 2140113)
1. Determination of phosphonoformic acid in human plasma and urine by high-performance liquid chromatography with electrochemical detection. Hassanzadeh MK; Aweeka FT; Wu S; Jacobson MA; Gambertoglio JG J Chromatogr; 1990 Jan; 525(1):133-40. PubMed ID: 2140113 [TBL] [Abstract][Full Text] [Related]
2. Determination of phosphonoformate (foscarnet) in biological fluids by ion-pair reversed-phase liquid chromatography. Pettersson KJ; Nordgren T; Westerlund D J Chromatogr; 1989 Mar; 488(2):447-55. PubMed ID: 2526150 [TBL] [Abstract][Full Text] [Related]
3. Determination of foscarnet (trisodium phosphonoformate) in pharmaceutical preparations by high-performance liquid chromatography with ultraviolet detection. García J; Márquez A; Ruiz R; López LF; Claro C; Lucero MJ Biomed Chromatogr; 2006 Oct; 20(10):1024-7. PubMed ID: 16583452 [TBL] [Abstract][Full Text] [Related]
4. Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients. Klintmalm G; Lönnqvist B; Oberg B; Gahrton G; Lernestedt JO; Lundgren G; Ringdén O; Robert KH; Wahren B; Groth CG Scand J Infect Dis; 1985; 17(2):157-63. PubMed ID: 2992074 [TBL] [Abstract][Full Text] [Related]
5. Determination of N-(phosphonacetyl)-L-aspartic acid (PALA) in plasma and urine by high pressure liquid chromatography. Lankelma J; Penders PG; Leyva A; Pinedo HM Eur J Cancer (1965); 1980 Nov; 16(11):1483-7. PubMed ID: 7227423 [No Abstract] [Full Text] [Related]
6. Clinical experiences with phosphonoformate (foscarnet) treatment of viral diseases following renal transplantation. Ahlmén J; Wijnween AC; Brynger H; Lycke E Scand J Urol Nephrol Suppl; 1985; 92():41-4. PubMed ID: 3008316 [TBL] [Abstract][Full Text] [Related]
7. Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation. Ganly PS; Arthur C; Goldman JM; Schulenburg WE Postgrad Med J; 1988 May; 64(751):389-91. PubMed ID: 2849092 [TBL] [Abstract][Full Text] [Related]
8. Foscarnet prophylaxis in marrow transplant recipients. Ringden O; Lonnqvist B; Aschan J; Sundberg B Bone Marrow Transplant; 1989 Nov; 4(6):713. PubMed ID: 2555006 [No Abstract] [Full Text] [Related]
9. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. Reusser P; Gambertoglio JG; Lilleby K; Meyers JD J Infect Dis; 1992 Sep; 166(3):473-9. PubMed ID: 1323614 [TBL] [Abstract][Full Text] [Related]
10. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. Jacobson MA; Gambertoglio JG; Aweeka FT; Causey DM; Portale AA J Clin Endocrinol Metab; 1991 May; 72(5):1130-5. PubMed ID: 1827127 [TBL] [Abstract][Full Text] [Related]
11. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Chrisp P; Clissold SP Drugs; 1991 Jan; 41(1):104-29. PubMed ID: 1706982 [TBL] [Abstract][Full Text] [Related]